CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors - a smart fighter that destroys cancer cells for days without tiring. USC biomedical engineers have made ...

CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...

This figure shows primary T cells modified using two approaches. CAR receptors are introduced through targeted DNA insertion (top), while CRISPRoff mRNA and guide RNAs silence additional genes through ...

Killer immune cells destroy cancer cells and cells infected by virus. These CD8 + T cells are activated after detection of viral infection or growth of “non-self” tumor cells. However, in chronic ...

Ohio State researchers have discovered that exhausted T cells collapse under the weight of misfolded proteins, activating a destructive stress response called TexPSR. Unlike normal stress systems, ...

Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer in mice—effectively ...